Annual Total Expenses
$587.65 M
-$8.24 M-1.38%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual total expenses is $587.65 million, with the most recent change of -$8.24 million (-1.38%) on December 31, 2023.
- During the last 3 years, PCRX annual total expenses has risen by +$209.52 million (+55.41%).
- PCRX annual total expenses is now -1.38% below its all-time high of $595.90 million, reached on December 31, 2022.
Performance
PCRX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$146.62 M
-$425.00 K-0.29%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly total expenses is $146.62 million, with the most recent change of -$425.00 thousand (-0.29%) on September 30, 2024.
- Over the past year, PCRX quarterly total expenses has increased by +$3.77 million (+2.64%).
- PCRX quarterly total expenses is now -7.03% below its all-time high of $157.71 million, reached on December 31, 2022.
Performance
PCRX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
PCRX Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.4% | +2.6% |
| 3 y3 years | +55.4% | +7.6% |
| 5 y5 years | +83.8% | +7.6% |
PCRX Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -1.4% | +43.8% | -7.0% | +28.3% |
| 5 y | 5-year | -1.4% | +55.4% | -7.0% | +80.5% |
| alltime | all time | -1.4% | +1476.7% | -7.0% | +1687.9% |
Pacira BioSciences Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $146.62 M(-0.3%) |
| Jun 2024 | - | $147.05 M(-3.3%) |
| Mar 2024 | - | $152.00 M(+3.2%) |
| Dec 2023 | $587.65 M(-1.4%) | $147.28 M(+3.1%) |
| Sep 2023 | - | $142.85 M(-2.3%) |
| Jun 2023 | - | $146.20 M(-3.4%) |
| Mar 2023 | - | $151.32 M(-4.1%) |
| Dec 2022 | $595.90 M(+45.8%) | $157.71 M(+8.3%) |
| Sep 2022 | - | $145.69 M(-6.8%) |
| Jun 2022 | - | $156.23 M(+14.7%) |
| Mar 2022 | - | $136.26 M(+19.2%) |
| Dec 2021 | $408.70 M(+8.1%) | $114.33 M(+19.0%) |
| Sep 2021 | - | $96.05 M(-4.5%) |
| Jun 2021 | - | $100.60 M(+3.0%) |
| Mar 2021 | - | $97.72 M(-7.3%) |
| Dec 2020 | $378.13 M(-1.9%) | $105.43 M(+6.3%) |
| Sep 2020 | - | $99.17 M(+22.1%) |
| Jun 2020 | - | $81.23 M(-12.0%) |
| Mar 2020 | - | $92.30 M(-14.3%) |
| Dec 2019 | $385.32 M(+20.5%) | $107.75 M(+13.8%) |
| Sep 2019 | - | $94.65 M(+0.8%) |
| Jun 2019 | - | $93.92 M(+5.5%) |
| Mar 2019 | - | $88.99 M(+7.5%) |
| Dec 2018 | $319.80 M(+4.3%) | $82.80 M(+6.0%) |
| Sep 2018 | - | $78.14 M(+1.0%) |
| Jun 2018 | - | $77.40 M(-5.0%) |
| Mar 2018 | - | $81.45 M(+15.5%) |
| Dec 2017 | $306.70 M(-0.5%) | $70.50 M(-0.2%) |
| Sep 2017 | - | $70.65 M(-14.1%) |
| Jun 2017 | - | $82.22 M(-1.3%) |
| Mar 2017 | - | $83.33 M(+10.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $308.39 M(+28.7%) | $75.36 M(-15.5%) |
| Sep 2016 | - | $89.22 M(+17.3%) |
| Jun 2016 | - | $76.08 M(+12.3%) |
| Mar 2016 | - | $67.73 M(-3.4%) |
| Dec 2015 | $239.54 M(+18.1%) | $70.13 M(+22.8%) |
| Sep 2015 | - | $57.10 M(-0.4%) |
| Jun 2015 | - | $57.33 M(+4.3%) |
| Mar 2015 | - | $54.98 M(+2.0%) |
| Dec 2014 | $202.83 M(+46.1%) | $53.87 M(+1.6%) |
| Sep 2014 | - | $53.03 M(+6.1%) |
| Jun 2014 | - | $50.01 M(+8.9%) |
| Mar 2014 | - | $45.92 M(+5.8%) |
| Dec 2013 | $138.84 M(+57.1%) | $43.38 M(+20.3%) |
| Sep 2013 | - | $36.07 M(+23.7%) |
| Jun 2013 | - | $29.15 M(-3.6%) |
| Mar 2013 | - | $30.23 M(+15.0%) |
| Dec 2012 | $88.38 M(+70.7%) | $26.28 M(+8.6%) |
| Sep 2012 | - | $24.19 M(+27.5%) |
| Jun 2012 | - | $18.97 M(+0.2%) |
| Mar 2012 | - | $18.94 M(+18.9%) |
| Dec 2011 | $51.77 M(+38.9%) | $15.93 M(+25.5%) |
| Sep 2011 | - | $12.69 M(+4.3%) |
| Jun 2011 | - | $12.17 M(+10.8%) |
| Mar 2011 | - | $10.98 M(+33.9%) |
| Dec 2010 | $37.27 M(-14.4%) | $8.20 M(-25.3%) |
| Sep 2010 | - | $10.98 M(+26.5%) |
| Jun 2010 | - | $8.68 M(-7.6%) |
| Mar 2010 | - | $9.40 M(-22.3%) |
| Dec 2009 | $43.55 M(-26.5%) | $12.09 M(+22.4%) |
| Sep 2009 | - | $9.88 M |
| Dec 2008 | $59.29 M | - |
FAQ
- What is Pacira BioSciences annual total expenses?
- What is the all time high annual total expenses for Pacira BioSciences?
- What is Pacira BioSciences annual total expenses year-on-year change?
- What is Pacira BioSciences quarterly total expenses?
- What is the all time high quarterly total expenses for Pacira BioSciences?
- What is Pacira BioSciences quarterly total expenses year-on-year change?
What is Pacira BioSciences annual total expenses?
The current annual total expenses of PCRX is $587.65 M
What is the all time high annual total expenses for Pacira BioSciences?
Pacira BioSciences all-time high annual total expenses is $595.90 M
What is Pacira BioSciences annual total expenses year-on-year change?
Over the past year, PCRX annual total expenses has changed by -$8.24 M (-1.38%)
What is Pacira BioSciences quarterly total expenses?
The current quarterly total expenses of PCRX is $146.62 M
What is the all time high quarterly total expenses for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total expenses is $157.71 M
What is Pacira BioSciences quarterly total expenses year-on-year change?
Over the past year, PCRX quarterly total expenses has changed by +$3.77 M (+2.64%)